This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Can J&J's Pipeline Progress in 2025 Aid Long-Term Growth?
by Kinjel Shah
JNJ's rapidly advancing pipeline, new drug approvals and expanding cancer and neuroscience portfolio could fuel growth through the next decade.
AZNPositive Net Change JNJNegative Net Change PFEPositive Net Change MRKPositive Net Change
pharmaceuticals
Company News for Dec 26, 2025
by Zacks Equity Research
Companies In The News Are: NVDA, NKE, AAPL, DVAX, SNY, INTC.
INTCPositive Net Change SNYPositive Net Change AAPLNegative Net Change DVAXNo Net Change NKEPositive Net Change NVDAPositive Net Change
biotechnology pharmaceuticals retail semiconductor
Top Stock Reports for AbbVie, Coca-Cola & Chevron
by Mark Vickery
ABBV, KO and CVX headline Zacks' top stock reports as analysts flag growth drivers, strategic moves and key headwinds shaping 2025 outlooks.
CVXNegative Net Change KONegative Net Change BDXPositive Net Change RSGPositive Net Change AJGPositive Net Change ABBVPositive Net Change PRPONegative Net Change ICCCPositive Net Change
consumer-staples medical oil-energy pharmaceuticals
FDA Issues CRL to SNY's Regulatory Filing for Multiple Sclerosis Drug
by Zacks Equity Research
Sanofi receives an FDA CRL for tolebrutinib in nrSPMS after multiple review extensions. The EC clears Wayrilz for treating immune thrombocytopenia.
SNYPositive Net Change CRMDPositive Net Change CSTLNegative Net Change
pharmaceuticals
PFE's Oncology & Obesity Pipeline Position It for Post-LOE Growth
by Kinjel Shah
Pfizer faces revenue pressure from 2026-2030 LOEs but is betting on a strengthened oncology and obesity pipeline to fuel sustainable post-LOE growth.
AZNPositive Net Change JNJNegative Net Change PFEPositive Net Change MRKPositive Net Change
pharmaceuticals
Soft Weekly Jobless Claims Data
by Zacks Equity Research
Soft Weekly Jobless Claims Data.
SNYPositive Net Change DVAXNo Net Change ADPPositive Net Change
biotechnology business-services pharmaceuticals
NVO's First Oral Obesity Pill Approval: What Does it Mean for Lilly?
by Kinjel Shah
NVO secures FDA approval for its first oral obesity pill, Wegovy, giving it a first-to-market edge and raising questions about Lilly's next move.
NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change GPCRNegative Net Change
pharmaceuticals
Xmas Eve Jobless Claims: Still Accommodating
by Mark Vickery
Despite today being Christmas Eve and markets closing at 1pm ET, we see new Weekly Jobless Claims numbers ahead of today's opening bell.
SNYPositive Net Change DVAXNo Net Change ADPPositive Net Change
earnings pharmaceuticals staffing
Amgen Strikes Drug Pricing Deal With Trump: What Investors Should Know
by Sundeep Ganoria
AMGN signs a pricing deal with the Trump administration, cutting U.S. drug costs, expanding DTC access and securing tariff relief tied to domestic investment.
GSKPositive Net Change BMYNegative Net Change MRKPositive Net Change AMGNNegative Net Change
biotechs medical pharmaceuticals
Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise
by Zacks Equity Research
SNY's $2.2 billion deal for Dynavax adds Heplisav-B, a shingles candidate, and other vaccine programs, strengthening its adult vaccine franchise and pipeline.
SNYPositive Net Change DVAXNo Net Change CRMDPositive Net Change CSTLNegative Net Change
biotechnology biotechs medical pharmaceuticals vaccines
The Zacks Analyst Blog Highlights Invesco, Johnson & Johnson, NiSource, Bunge Global and Morgan Stanley
by Zacks Equity Research
Invesco leads Zack' list of five high-yield S&P 500 stocks, highlighting dividend strength and steady income potential for 2026.
MSPositive Net Change NINegative Net Change JNJNegative Net Change IVZNegative Net Change BGPositive Net Change
agriculture finance pharmaceuticals utilities
These 3 Medical Stocks Have Wall Street's Bullish Vote for 2026
by Kaibalya Pravo Dey
COR, ADUS and SEM earn bullish analyst support for 2026 as AI adoption, home care demand and facility expansion fuel medical sector growth.
CORPositive Net Change SEMNegative Net Change ADUSNegative Net Change
medical pharmaceuticals
Company News for Dec 24, 2025
by Zacks Equity Research
Companies In The News Are: NVO, HII, NOW, ZIM.
NVONegative Net Change HIINegative Net Change NOWPositive Net Change ZIMPositive Net Change
aerospace computers pharmaceuticals transportation
Will the Recent Pricing Deal With the Government Impact BMY's Sales?
by Ekta Bagri
BMY has agreed to supply Eliquis free of charge to Medicaid starting in 2026 and will also donate seven tons of the active pharmaceutical ingredient used in Eliquis.
BMYNegative Net Change JNJNegative Net Change PFEPositive Net Change MRKPositive Net Change
biotechnology biotechs medical pharmaceuticals
ABBV vs. AZN: Which Pharma Stock is the Better Investment Now?
by Sundeep Ganoria
AbbVie and AstraZeneca both bring blockbuster drugs, deep pipelines and risks, but their growth paths, pressures and priorities now sharply diverge.
AZNPositive Net Change ABBVPositive Net Change
biotechs medical pharmaceuticals vaccines
Novo Nordisk Wins FDA Nod for Oral Wegovy in Obesity, Stock Up
by Zacks Equity Research
NVO stock up as it wins FDA approval for oral Wegovy in obesity, becoming the first oral GLP-1 RA indicated for weight management.
NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
The Zacks Analyst Blog Highlights Eli Lilly, Shell, ICICI Bank, Frequency Electronics and Vaso
by Zacks Equity Research
Eli Lilly anchors Zacks' latest Analyst Blog, with new research highlighting pharma growth drivers alongside global energy and banking insights.
LLYPositive Net Change IBNPositive Net Change FEIMNegative Net Change VASOPositive Net Change SHELNegative Net Change
computers finance medical-devices oil-energy pharmaceuticals
Novo Nordisk vs. Amgen: Which Healthcare Stock Is the Smarter Choice?
by Ahan Chakraborty
NVO and AMGN square off as GLP-1 leadership, pipeline depth, and diversification set up a compelling healthcare stock comparison.
NVONegative Net Change LLYPositive Net Change AMGNNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
5 Big Drug Stocks That May Continue to Outperform in 2026
by Kinjel Shah
Five big drugmakers, including LLY and JNJ, are riding innovation, dealmaking and pipeline momentum that could help them keep outperforming in 2026.
AZNPositive Net Change JNJNegative Net Change LLYPositive Net Change AMGNNegative Net Change ABBVPositive Net Change
biotechs pharmaceuticals
J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant (Revised)
by Zacks Equity Research
JNJ wins FDA approval for a subcutaneous version of Rybrevant, cutting treatment time to minutes and boosting convenience across NSCLC indications.
AZNPositive Net Change JNJNegative Net Change HALOPositive Net Change
biotechs medical pharmaceuticals
Top Analyst Reports for Eli Lilly, Shell & ICICI Bank
by Mark Vickery
LLY's strong GLP-1 demand, international launches and new drug contributions highlight why it leads today's top analyst reports lineup.
LLYPositive Net Change DBPositive Net Change IBNPositive Net Change GMPositive Net Change MKLNegative Net Change FEIMNegative Net Change VASOPositive Net Change SHELNegative Net Change
computers finance medical-devices oil-energy pharmaceuticals
J&J Stock Trading Above 50- & 200-Day SMA for 6 Months: How to Play
by Kinjel Shah
J&J has been trading above its 50- and 200-day SMAs for six months as strong 2025 execution, new drugs and pipeline progress support bullish momentum.
JNJNegative Net Change AMGNNegative Net Change TEVAPositive Net Change
pharmaceuticals
What Awaits These 4 Biotech Stocks That More Than Doubled in 2025
by Ahan Chakraborty
IONS, GPCR, MNPR and KOD more than double in 2025 as policy clarity, M&A revival and clinical wins lift biotech momentum into 2026.
IONSNegative Net Change KODNegative Net Change MNPRNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Cytokinetics Wins FDA Approval for Cardiovascular Drug, Stock up
by Zacks Equity Research
CYTK enters a new era as FDA approval of Myqorzo transforms it into a commercial biotech, opening a long-term growth runway in cardiology.
BMYNegative Net Change FOLDNo Net Change CYTKNegative Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Drug Sector on a High as 9 Drugmakers Strike Drug Pricing Deals
by Sundeep Ganoria
Amgen and eight other pharma giants struck deals with the Trump administration to cut U.S. drug prices while gaining tariff relief and manufacturing incentives.
GSKPositive Net Change BMYNegative Net Change MRKPositive Net Change AMGNNegative Net Change GILDNegative Net Change
biotechs medical pharmaceuticals